hVIVO plc (LON:HVO - Get Free Report)'s share price fell 46.3% during trading on Friday . The stock traded as low as GBX 6.50 ($0.09) and last traded at GBX 8.70 ($0.12). 83,062,000 shares were traded during trading, an increase of 2,325% from the average session volume of 3,424,608 shares. The stock had previously closed at GBX 16.20 ($0.22).
Analyst Ratings Changes
Separately, Shore Capital restated a "buy" rating on shares of hVIVO in a research report on Friday.
View Our Latest Report on HVO
hVIVO Trading Down 46.3%
The company has a current ratio of 1.61, a quick ratio of 1.16 and a debt-to-equity ratio of 33.86. The firm has a 50-day moving average of GBX 16.16 and a 200 day moving average of GBX 18.04. The company has a market cap of £61.56 million, a P/E ratio of 3.59 and a beta of 0.97.
hVIVO (LON:HVO - Get Free Report) last announced its earnings results on Thursday, April 10th. The company reported GBX 1.69 ($0.02) EPS for the quarter. hVIVO had a return on equity of 47.93% and a net margin of 25.96%. On average, analysts predict that hVIVO plc will post 1.5492958 earnings per share for the current fiscal year.
Insider Activity at hVIVO
In other hVIVO news, insider Yamin Mo' Khan sold 3,062,246 shares of the stock in a transaction that occurred on Thursday, March 6th. The stock was sold at an average price of GBX 17 ($0.23), for a total value of £520,581.82 ($700,648.48). 14.03% of the stock is owned by corporate insiders.
About hVIVO
(
Get Free Report)
hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.
See Also
Before you consider hVIVO, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and hVIVO wasn't on the list.
While hVIVO currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
